Member Info for SEA7

And I have just picked up two tranches at 48.09 and then at 47.999 as it dropped a bit further

Trade reporting software in the UK simply takes the mid price at the time the trade was printed - if it is above, it is recorded as a buy and below mid, a sell.

Jono,

thanks for that point - the valuation for the company is based on, everything having been taken out, so the figure attributable to shareholders in the accounts, takes into consideration the fact that only 42.53% of the attributable revenue for uniteds share is received by the company.

as for the point re number of barrels - yes, I did a "range of one year" based on 462 bopd, and gave gross revenue at the same price used by the other poster - sorry didn't specify in that revenue figure, re the tax take by Egypt gov. - should have made it clearer

IMO and we all have different views on it, ...

net assets after all liabilities are about £16m in last accounts

After all taxes and charges on revenue - the total attributable to shareholders was £2.3m

from a valuation perspective as at the last accounts - you could say that £18.3 million is the current value of the company

that would imply a share price of about 3p

sales of assets, farm outs and positive drilling excluded from above

The rns is correct but it refers to total recovery and not just uniteds 22% ownership

Back in march 2022...

ASD2 Well....The well has now been tied into the existing facilities and brought on stream at an initial rate of c. 2,100 bopd gross (462 bopd net) on a 28/64" choke.

as united hold a 22% share of the field, it means that out of the 2100 bopd, 462 are attributable to united.

This would imply revenue of 168,630 barrels in a year or about $11m at circa $66 a barrel to united.

Solid buying all morning - leaky ship maybe!

Maths is the same in o and g, but it is probability not odds that are used..

4 to 1 odds

This means that out of 5 possible outcomes, odds are that there will be 4 of one kind of outcome and 1 of another kind of outcome.

This drill cannot be 4 to 1 odds, as there are not 5 possible outcomes - just success or not.

4 to 1 probability

There is a 80.00 percent probability of a particular outcome and 20.00 percent probability of another outcome.

this is how the drill cos is seen in the industry as i understand it - probability not odds.

Odds vs. Probability

Note that odds and probability are not the same. Odds compare one event to another event, whereas probability compares one event to both possible events. Thus, when the odds are 4 to 1, the fraction for the Odds is 4/1, but the fraction to calculate the probability is 4/5.

hence 4/5 chance of success or 80% on this drill

You will of course be aware that quattro is subject to a reverse takeover by jesmond capital in canada and they are "planning" a non brokered private placement to fund the qualifying transaction. They expect the reverse takeover and closure of deal with united to occur concurrently.

https://www.sedar.com/DisplayCompanyDocuments.do?lang=EN&issuerNo=00050742

you will need to click on "1 May 2023 MD&A English" for the discussion surrounding the RTO of quattro by jesmond and the plan to raise money to pay for uniteds asset

Http://envoi.co.uk/wp-content/uploads/2023/04/UOG%20Walton%20Morant%20Update%20Flyer%20April%202023.pdf

The potential for 7+ billion barrels of mid case prospective resources.

https://www.afr.com/street-talk/small-caps-aura-energy-iperionx-chasing-equity-20230501-p5d4la

Uranium explorer Aura Energy was seeking $9 million via an institutional placement and a further $1 million via a share purchase plan, according to a term sheet seen by Street Talk.

The offer was priced at 18¢ a share, a 19.5 per cent discount to the last traded price. The board and management intend to subscribe for approximately $100,000 under the SPP.

Aura’s raise comes after the company tested the waters with a $5 million raise in March last year to nudge its Mauritanian uranium project Tiris into production.

htTps://finance.yahoo.com/news/uraniums-impressive-performance-troubled-times-130000500.html

Uranium was the only commodity to increase in value in February, as the price of nearly every other major raw material declined.

As the push to replace fossil fuels with lower-emission energy sources gains momentum, uranium has exited its decade-long downturn and professionals in the industry are excited about the sector's future.

today...

https://world-nuclear-news.org/Articles/Energoatom-and-Cameco-sign-fuel-and-uranium-agreem?feed=feed

The first of the bilateral agreements signed will see Cameco meeting 100% of Energoatom's need for natural uranium hexafluoride from 2024 to 2035 for the nine nuclear reactors at the Rivne, Khmelnitsky and South Ukraine plants for the duration of the contract. These plants have combined requirements over the contract term of some 15.3 million kgU as UF6 - equivalent to 40.1 million pounds U3O8 (15,424 tU).}

The second agreement covers the sale of Ukrainian uranium to Canada, with conversion of the uranium being provided by Cameco.

Kotin said that the two agreements paved the way for concluding a third agreement, on specific quantities of uranium product supply, adding: "Cooperation with Cameco is strategic and necessary for Energoatom, because together with Westinghouse we continue to move to Western standards. The development of domestic nuclear energy is possible only thanks to cooperation with our international partners."

from Kazatomprom results release today...period ending dec 31st 2022

https://www.investegate.co.uk/jsc-nac-kazatomprom--kap-/rns/kazatomprom-2022-financial-results/202303170700013469T/

The decrease in production guidance for 2023 in comparison to 2022 is mainly due to continued delays and/or limited access to certain key materials, including sulfuric acid, and equipment impacting the wellfield commissioning schedule in 2022.

and

Wellfield development, procurement and supply chain issues, including inflationary pressure on production materials and reagents, are expected to continue throughout 2023, impacting the Company's financial metrics and giving rise to an expectation that C1 cash cost and All-in Sustaining cash cost will be higher in 2023 than in 2022 Changes to the tax code of the Republic of Kazakhstan on Mineral Extraction Tax, which came into effect in 2023, will have an additional impact on the Company's financial performance. The expenditures related to the local social funding requests are possible as well. However, these risks cannot be quantified or estimated at this time.

and

The Company continues to target an ongoing inventory level of approximately six to seven months of annual attributable production The Company may purchase uranium from the spot market, while continuing to monitor market conditions for opportunities to optimise its inventory.

good luck on your next trade charlotte - I am staying for montara restart and then re-assess - I have been in and out of this over the recent months and banked decent profits

it is an equity product - and is sold off like everything else in these markets

i have added today - such a discount

https://www.georginaenergy.com/projects/mt-winter/

The EP 155 Mt Winter Project, in the Northern Amadeus Basin, Northern Territory of Australia is considered by independent consultants to be one of the potentially most valuable Hydrogen, Helium and natural gas prospects in Australia.

The property is held by AIM listed Mosman Oil Gas Plc and Westmarket Oil Gas, a wholly owned subsidiary of Georgina Energy Plc, via a formal Farm-in agreement has rights to earn up to a 90% working interest with Operatorship.

aka

Interactive Prospect Targeting Holdings Plc (AIM:IPH
woodburne square

StratMin Global Resources Plc

From that RNS... the market will need confirmation of the renewal of the home office licence, as it expired on the 12th Jan 2023 before we see any real traction and interest.

Celadon will require receipt of confirmation from the Home Office that they have updated its current Home Office licence before they will be able to supply its GMP API to third parties. The Company is informing the Home Office of the receipt of its GMP registration. Celadon's current Home Office licence permits it to legally grow high-THC medicinal cannabis for the purpose of producing test batches of cannabis oil to support its application to the MHRA; during 2022, Celadon achieved seven successful harvests. Whilst there is no guarantee that the Home Office will update the current licence, nor any timeframe for this, the Directors are confident that the licence will be updated in due course. The Company has worked closely with the Home Office for four years, including securing updates to its licence, and had the conversation about updating the licence for GMP at the Home Office's last site inspection.

and from the proposed acquisition document dated 28th feb 2022.

On 23 July 2021, Vertigrow's subsidary, CPL received a Home Office Licence following approval from the Medicines and Healthcare products Regulatory Agency (the "MHRA") to apply for the licence, allowing it to legally grow medicinal cannabis in the UK for the purpose of producing test batches of cannabis oil to support its application to the MHRA for registration as a manufacturer of medicinal product APIs. This licence was renewed on 12 January 2022 for a 12 month period and as part of that renewal CPL changed its analytical testing partner. The process of obtaining this licensing is complex, took over two years, required material investment and is technically extensive. The Directors and Proposed Directors believe this is one of the first such Home Office Licences granted in the UK. Following the satisfactory production of test batches of cannabis oil, Celadon will apply for MHRA registration and if this is successfully received, Celadon will also apply for a new licence from the Home Office. Once received, the new Home Office licence would be required to be renewed annually. The receipt of MHRA registration and a new Home Office licence will enable the business to then supply medicinal cannabis (in the form of an API to manufacturers of finished medicinal products, which in this case is an extracted oil used in the finished pharmaceutical product) with a high THC content in the UK, allowing it an opportunity to enter what is expected to be a substantial, extensively regulated and fast-growing UK market.